FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML

Share this post

The FDA has approved the first-in-class agent ivosidenib, which targets mutations in the IDH1 gene in acute myeloid leukemia.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply